Bladder cancer - European Society for Medical Oncology
Bladder cancer - European Society for Medical Oncology
Bladder cancer - European Society for Medical Oncology
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
IS BLADDER CANCER FREQUENT?<br />
It is estimated that in 2008, in Europe, approximately 110,500 patients were diagnosed with bladder<br />
<strong>cancer</strong>. <strong>Bladder</strong> <strong>cancer</strong> is, thus, the 5 th most common <strong>cancer</strong> in Europe.<br />
<strong>Bladder</strong> <strong>cancer</strong> is approximately five times more frequent in men than in women. It is estimated that<br />
in 2008, 27 out of 100,000 men and 5 out of 100,000 women developed bladder <strong>cancer</strong>. Of all<br />
<strong>cancer</strong>s, bladder <strong>cancer</strong> is the 4 th most common <strong>cancer</strong> in men, and the 13 th most common <strong>cancer</strong> in<br />
women.<br />
In the <strong>European</strong> Union, the likelihood <strong>for</strong> a man to develop bladder <strong>cancer</strong> at some point in his life<br />
lies between 1.5 and 2.5%. For men living in Flanders (Belgium), Malta, Spain and Italy this is<br />
somewhat higher: between 3.1 and 4.2%. For a woman in the <strong>European</strong> Union, the chances of<br />
developing bladder <strong>cancer</strong> at some point in her life are less than 1%.<br />
The risk of developing bladder <strong>cancer</strong> increases with age; overall, 70% of patients who develop<br />
bladder <strong>cancer</strong> present symptoms after the age of 65.<br />
<strong>Bladder</strong> <strong>cancer</strong>: a guide <strong>for</strong> patients‐ In<strong>for</strong>mation based on ESMO Clinical Practice Guidelines ‐v.2012.1 Page 4<br />
This document is provided by Reliable Cancer Therapies with the permission of ESMO.<br />
The in<strong>for</strong>mation in this document does not replace a medical consultation. It is <strong>for</strong> personal use only and cannot be modified,<br />
reproduced or disseminated in any way without written permission from ESMO and Reliable Cancer Therapies.